Loading...
PARP Inhibition: “Targeted” Therapy for Triple Negative Breast Cancer
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating advanced triple negative breast cancer (TNBC) are lacking. PARP (Poly-(adenosine diphosphate [ADP]-ribose) polymerase) inhibitors are emerging as one of the most promising ‘targeted’ therapeutics to...
Na minha lista:
Main Authors: | , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
2010
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948607/ https://ncbi.nlm.nih.gov/pubmed/20858840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0939 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|